The “Clindamycin Phosphate Topical Market” report delivers a comprehensive analysis of the industry, providing valuable insights into its SWOT analysis, growth prospects, and anticipated CAGR. It ...

(RTTNews) - India-based Glenmark Pharmaceuticals Inc.'s USA subsidiary, Thursday announced the launch of Clindamycin Phosphate Foam, 1 percent for the treatment of acne. The company added that ...

1 Glenmark's Clindamycin Phosphate Foam, 1% is only approved for the indication(s) listed in Glenmark's approved label. 2 All brand names and trademarks are the property of their respective owners.

Medtronic plc , a global leader in healthcare technology, today released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international head-to ...

1 Glenmark’s Clindamycin Phosphate Foam, 1% is only approved for the indication(s) listed in Glenmark’s approved label. 2 All brand names and trademarks are the property of their respective owners. 3 ...

Calix and the old Pilbara Minerals announced on Thursday they would resume work on their first-of-a-kind lithium phosphate processing plant in Western Australia, reversing an October decision to ...

Investing.com -- Glenmark Pharmaceuticals (NSE:GLEN) Inc., USA, has announced the launch of Clindamycin Phosphate Foam, 1%, a product that is bioequivalent and therapeutically equivalent to Evoclin® ...

Clindamycin Phosphate Foam, 1% is indicated for the treatment of acne vulgaris, providing an effective solution for patients seeking topical treatment options. Glenmark’s product offering mirrors the ...